Boehringer Ingelheim distinguished as number one Top Employer 2007 by Science Magazine

Boehringer IngelheimBoehringer Ingelheim has been ranked first among the top employers in the pharmaceutical and biopharmaceutical industry according to the 2007 Top Employers survey conducted by Science. Science's annual survey polls employees in biotechnology, biopharmaceutical, pharmaceutical, and related industries. Each company received a ranking on the basis of whether it treats its employees with respect, whether its work-culture values align with employees' personal values, and multiple other factors.

In the past few years that Science has carried out this survey, Boehringer Ingelheim has climbed up in ranking, from 8th place in 2005 to second place last year. This year, Boehringer Ingelheim has reached the top ranking, recognizing the company’s strong commitment to innovative thinking throughout the product pipeline, from the laboratory to the marketplace, while establishing an excellent working environment.

"This success has not been created overnight. Rather, it is a result of decades of Boehringer Ingelheim's dedication to research and innovation as the drivers for producing new and better medicines for patients," states Mikael Dolsten, Executive Vice President Pharma Research at Boehringer Ingelheim, highlighting the critical importance of innovation. "In a strong science-driven industry, we direct our projects in a climate balancing continuity and change in which we constantly challenge ourselves by seeking a creative dialogue with internal and external experts."

Recruiting the right people, inculcating them with the corporation's values, providing them with scientific challenges, and including them in discussion of the company’s goals have played major roles in Boehringer Ingelheim's success.

"Our process started in the early 1990s, when we developed a corporate vision which was reloaded in 2004 with a concept called 'Lead and Learn'", explains Hans-Joachim Geppert, head of Human Resources at Boehringer Ingelheim. "The guiding principles of this vision have resulted in a great culture of trust and loyalty among our employees, who remain with the company for an exceptional average of 13 years" he adds.

This year's Science survey identified 19 additional companies to represent the top 20 of the best employers from the list of 477 companies in the biotechnology and pharmaceutical industry.

Equally attractive to current and would-be employees, Boehringer Ingelheim's management aims for nimbleness in its operations. Dolsten points out that "the company has the critical mass and resources to discover new innovative drugs and, at the same time, strives to be a simple, dynamic and efficient global organisation".

Science's 2007 Top Employers Survey
Respondents to the Science Top Employer web-based survey are asked to rate companies based on 23 driving characteristics, including financial strength, easy adaptation to change, and a research-driven environment. Survey respondents were asked to write in the names of companies they considered best, average and worst employers. They then rated these companies on 23 different attributes. Attribute categories included Corporate Image, Leadership and Direction, Financial Prowess, Work Culture/Environment, Work/Life Balance, Academics and Collegial Exchange, and Compensation and Benefits. Survey responses were analyzed by Senn-Delaney Culture Diagnostics & Measurement, which used a mathematical process to assign a unique score to rate the companies’ employer reputation.

The report is based on a total sample of 3,157 people in the industry. Nearly one-third (29%) of participants came from outside the United States - primarily Western Europe. Details of the survey results and individual company rankings will be published in the 12 October 2007 issue of Science.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2006, Boehringer Ingelheim posted net sales of 10.6 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development.

For further information, visit www.boehringer-ingelheim.com.

Most Popular Now

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

Nucala (mepolizumab) gains FDA approval for two ne…

GlaxoSmithKline (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinjec...

Jeff Settleman, Ph.D., joins Pfizer to lead Oncolo…

Pfizer Inc. (NYSE: PFE) announced that Jeff Settleman, Ph.D., will join the company as Senior Vice President and Group Head of Oncology Research & Development, leading al...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

Full data from CAROLINA® outcome trial support lon…

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced full data from the CAROLINA® trial demonstrating that Trajenta® (linagliptin) did not increase cardio...

Cleveland researchers test novel gene therapy for …

A novel gene therapy clinical trial at University Hospitals Seidman Cancer Center and the Case Comprehensive Cancer Center is showing promising results, garnering funding...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Bristol-Myers Squibb announces post-closing leader…

Bristol-Myers Squibb Company (NYSE:BMY) today announced the future leadership team of the combined company effective upon completion of the company’s pending merger with ...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Prescription drug costs steadily soar, yet price t…

After reviewing tens of millions of insurance claims for the country’s 49 most popular brand-name prescription drugs, a team from Scripps Research Translational Institute...